Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Hypericum extract reverses S-ketamine-induced changes in auditory evoked potentials in humans - possible implications for the treatment of schizophrenia.

Murck H, Spitznagel H, Ploch M, Seibel K, Schaffler K.

Biol Psychiatry. 2006 Mar 1;59(5):440-5. Epub 2005 Sep 13.

PMID:
16165104
2.

Effects of Hypericum extract (LI160) on the change of auditory evoked potentials by cortisol administration.

Murck H, Uhr M, Schaffler K, Seibel K.

Neuropsychobiology. 2004;50(2):128-33.

PMID:
15292666
3.

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC.

Arch Gen Psychiatry. 2000 Dec;57(12):1139-47.

PMID:
11115327
4.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
5.

Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.

D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M.

Biol Psychiatry. 2012 Nov 1;72(9):785-94. doi: 10.1016/j.biopsych.2012.05.009. Epub 2012 Jun 19.

PMID:
22717030
6.

[Acoustic evoked potentials of medium latency. Anesthesia induction with S-(+)-ketamine versus ketamine racemate].

Schwender D, Faber-Züllig E, Fett W, Klasing S, Finsterer U, Peter K.

Anaesthesist. 1993 May;42(5):280-7. German.

PMID:
8317684
7.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
8.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
9.

Mid-latency auditory evoked potentials in humans during anesthesia with S (+) ketamine--a double-blind, randomized comparison with racemic ketamine.

Schwender D, Faber-Züllig E, Fett W, Klasing S, Finsterer U, Pöppel E, Peter K.

Anesth Analg. 1994 Feb;78(2):267-74.

PMID:
8311278
10.

[Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].

Micallef J, Tardieu S, Gentile S, Fakra E, Jouve E, Sambuc R, Blin O.

Neurophysiol Clin. 2003 Jun;33(3):138-47. French.

PMID:
12909392
11.

Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients.

LaPorte DJ, Lahti AC, Koffel B, Tamminga CA.

J Psychiatr Res. 1996 Sep-Oct;30(5):321-30.

PMID:
8923336
12.

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.

Piskulić D, Olver JS, Maruff P, Norman TR.

Hum Psychopharmacol. 2009 Aug;24(6):437-46. doi: 10.1002/hup.1046.

PMID:
19637398
13.

Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.

Boeijinga PH, Soufflet L, Santoro F, Luthringer R.

J Psychopharmacol. 2007 May;21(3):321-37. Erratum in: J Psychopharmacol. 2007 Nov;21(8):900.

PMID:
17591659
14.

Differentiating cortical patterns of cognitive dysfunction in schizophrenia and posttraumatic stress disorder.

Galletly CA, McFarlane AC, Clark R.

Psychiatry Res. 2008 May 30;159(1-2):196-206. doi: 10.1016/j.psychres.2007.04.001. Epub 2008 Apr 18.

PMID:
18423610
15.

[Cognitive evoked potentials in patients with schizophrenia].

Chen X, Zhang M, Lou F.

Zhonghua Yi Xue Za Zhi. 1999 Sep;79(9):676-8. Chinese.

PMID:
11715457
16.

Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.

Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA.

Pharmacopsychiatry. 2005 Nov;38(6):301-11.

PMID:
16342002
17.

Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.

Ehrlichman RS, Maxwell CR, Majumdar S, Siegel SJ.

J Cogn Neurosci. 2008 Aug;20(8):1403-14. doi: 10.1162/jocn.2008.20097.

PMID:
18303985
18.

Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?

Stefanovic A, Brandner B, Klaassen E, Cregg R, Nagaratnam M, Bromley LM, Das RK, Rossell SL, Morgan CJ, Curran HV.

J Clin Psychopharmacol. 2009 Apr;29(2):124-33. doi: 10.1097/JCP.0b013e31819a4b91.

PMID:
19512973
19.

The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study.

Randløv C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K.

Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19.

PMID:
16423519
20.

Impact of modafinil on prefrontal executive function in schizophrenia.

Hunter MD, Ganesan V, Wilkinson ID, Spence SA.

Am J Psychiatry. 2006 Dec;163(12):2184-6.

PMID:
17151173

Supplemental Content

Support Center